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ABSTRACT
Introduction. Metabolic bone disease is a malady that causes 
significant morbidity and mortality to a patient who has sus-
tained a fragility fracture. There is currently no protocol to 
prevent secondary fragility fracture at our institution. The ob-
jective of this study was to create an appropriate protocol for 
implementing clinical pathways for physicians to diagnose and 
treat osteoporosis and fragility fractures by educating patients.
Methods. A multidisciplinary team created an appropri-
ate protocol that could be implemented in an inpatient set-
ting. A thorough literature review was conducted to evaluate 
potential barriers and efficacious methods of protocol design.
Results. A bone health improvement protocol was developed. 
Any patient over the age of 50 who sustains a fracture from low 
energy trauma, such as a fall from standing or less, should be 
considered to place into this protocol. These patients received 
education on metabolic bone disease, a prescription for high 
dose vitamin D therapy, and laboratory testing to determine 
the etiology of their metabolic bone disease. Continuity of care 
of these patients with their primary care provider was provid-
ed for further management of their metabolic bone disease and 
evaluation of their disease after discharged from the hospital.
Conclusion. Comprehensive secondary prevention should con-
sist of osteoporosis assessment and treatment together with a 
fall risk assessment. With this protocol, secondary fragility frac-
tures potentially could be prevented. KS J Med 2017;10(3):62-66.
INTRODUCTION
 Osteoporosis is a prevalent metabolic bone disease among the el-
derly. It is defined as a disorder with micro-architectural deteriora-
tion that impairs both bone structural properties and bone quality.1 
This is a significant public health issue that predisposes 50% of pa-
tients over age 50 to an increased risk for fragility fracture.1-5 Fragil-
ity fractures, defined as bone fractures resulting from a low-energy 
trauma such as a fall from a standing height or less, are a conse-
quence of low bone quality and density.6,7 These types of fractures 
are encountered most commonly in the hip, spine, distal radius, and 
proximal humerus. Hip fractures are the major cause of morbidity 
and mortality associated with osteoporosis and fragility fractures.1 
The risk of mortality for elders after a hip fracture due to low en-
ergy trauma is twice that of the general population. Osteoporosis 
and fragility fractures pose enormous challenges for both the indi-
vidual and society in terms of loss of independence, quality of life, 
and economic burden.8,9 These include long hospitalization, need 
for surgical treatment, increased disability, and partial or complete 
loss of the ability to perform activities of daily living independently. 
 El-Rabbany et al.10 found only 5 to 38% of patients with fra-
gility fractures were being treated for osteoporosis at final 
follow-up. Identifying patients at risk and getting the proper 
evaluation and treatment are not universal. A disconnect ex-
ists between the realization that fragility fractures are the stig-
mata of osteoporosis and the engagement of the patient and 
physician team toward more universal diagnosis and treatment. 
 Orthopedic residency and curricula may not provide sufficient 
knowledge or training to allow osteoporosis management.11 Ed-
wards et al.12 demonstrated a modest increase in certain aspects of 
bone health order pathways and treatment by using an electronic 
medical record order set. That intervention created with providers’ 
input increased the follow-up and treatment of patients with osteo-
porosis. This, however, failed to increase diagnosis or treatment for 
osteoporosis at the time of hospitalization for a fragility fracture. 
 No protocol exists to prevent secondary fragility fracture at our in-
stitution. The objective of this study was to create an appropriate pro-
tocol for implementing clinical pathways for physicians to diagnose 
and treat osteoporosis and fragility fractures by educating patients.
METHODS
 A multidisciplinary team, which consisted of physicians, nurse 
practitioners, physical therapists, nurse managers, and the ortho-
pedic service line coordinator, was assembled to create an appro-
priate protocol that could be implemented at a level 1 trauma center 
about metabolic bone disease and fragility fractures. This team was 
tasked with vetting the protocol to ensure feasibility in implemen-
tation at a clinical level as well as ease of modification after imple-
mentation. A thorough literature review was conducted to evaluate 
efficacious methods of protocol design and potential barriers to 
implementation. The literature reviews also encompassed treat-
ment goals for patients with osteoporosis and fragility fracture.
RESULTS
 A bone health protocol was developed by the multidisciplinary 
team (Figure 1). This protocol was created to improve care for pa-
tients at risk for fragility fracture or post-fracture which focused on 
initiating and facilitating the screen and treatment of osteoporosis. 
It divided into several strategic steps: scenario, lab tests, patient edu-
cation, vitamin D prescription, and primary care provider follow-up.
 Scenario. Orthopedic surgeons, trauma surgeons, and emer-
gency room (ER) providers often are the first clinicians to see the 
patients after a fragility fracture. A patient over the age of 50 who 
sustains a fracture to the appendicular skeleton caused by a low en-
ergy trauma event, such as a fall from standing height or less, should 
be placed into this protocol. The incidence and  lifetime risk of any 
fracture doubles every decade after 50 years old.4,11,13-15 During the 
visit, a standard medical history also should be obtained, with par-
ticular attention paid to age, weight, personal and family history of 
fracture, physical inactivity, medication, alcohol, tobacco, and frailty.
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Figure 1. The bone health protocol with treatment goals to be provided be-
fore the patient leaves the hospital. 
 Laboratory Tests (Blood Test). Although bone strength cannot 
be determined directly in vivo, with increased age comes a marked 
reduction in bone mass and destruction of bone architecture, lead-
ing to a considerable decrease in bone strength.16-18 Basic laboratory 
tests, such as a complete blood count, serum chemistry profile, and 
urinalysis, are usually requested by the clinicians during a regular 
medical checkup to monitor patient health. Adding a basic metabol-
ic profile, parathyroid hormone level, thyroid stimulating hormone, 
follicle-stimulating hormone level, luteinizing hormone level, and 
Vitamin D-25-hydroxy level to these tests would help in determin-
ing the ethology for metabolic bone disease. The results of these 
tests give clinicians insight into patient’s status regarding common 
etiologies of metabolic bone disease, including decreased vitamin 
D levels, hyperparathyroidism, hyperthyroidism, renal osteodystro-
phy, and hypogonadism. These tests are among the most effective in 
determining etiology of metabolic bone disease based on literature.19
 Patient Education. Patients with osteoporosis who have sus-
tained a fracture have a very high risk of suffering a new fracture, 
often within one year of original fracture.14,20-28 Therefore, before 
discharging the patients from the hospital, nursing staff, and health-
care providers must provide proper education to patients and their 
family members about metabolic bone disease. This includes acute 
management of the presenting fracture and prevention of second-
ary fragility fractures, the importance of vitamin D and calcium 
supplementation, bone mineral density (BMD) testing, the possible 
need for anti-osteoporotic medications, home safety goals, smok-
ing cessation and alcohol moderation, and physical therapy for gait 
training and balance. Patients who underwent balance training 
and education had better balance measures and fear of falling out-
comes.29-31 Smokers should be advised to quit, patients with alco-
holism should be treated, and patients for whom risk factor analysis 
indicates a strong potential for osteoporosis should have an ultra-
sound of the heel as an initial screening tool every six months fol-
lowed by a bone densitometry (DEXA) scan in those identified as 
having low bone density.32 This education will allow patients and 
their family members to be involved in the patient’s bone health.
 Vitamin D Prescription. Vitamin D is essential for normal cal-
cium metabolism and maintenance of bone density, and the risk of 
deficiency increases with age.33-36 The prevalence of vitamin D de-
ficiency in 2010 in the U.S. was 41.6% with deficiency rates around 
49% in patients age 55 to 64 years.37 Due to the high levels of vita-
min D deficiency among elderly individuals and the delay in test re-
sults, which may take up to five days due to the specialized nature of 
the test and scarcity of laboratories that perform it, there is a benefit 
to start therapeutic cholecalciferol (vitamin D3) prophylactically 
before discharge from the hospital. Supplementation with vitamin 
D reduced bone loss and the incidence of non-vertebral fractures 
in men and women aged ≥65 years.38 Patients should be prescribed 
vitamin D supplementation (vitamin D3) for eight weeks at a dose 
of 1.25 mg or 50,000 international units (IU) once a week which is 
supported by previous studies.39-41 With this high dose of vitamin D 
supplementation (50,000 IU) cholecalciferol restored serum 25-hy-
droxy vitamin D (25(OH)D) levels to sufficient levels (i.e., above vi-
tamin D deficiency level of 50 nmol/L)42,43 among migrants and non-
migrants, especially for those with lower baseline serum 25(OH)D.
 Primary Care Provider Follow-up. The ultimate goal in treat-
ing fragility fracture patients with osteoporosis is not only acute 
management of the presenting fracture, but also the prevention 
of subsequent fractures.7,44-47 The primary care providers are the 
crucial members that need to provide continuity of care with these 
patients on their metabolic bone disease management and further 
evaluation of their disease after the patient is discharged from the 
hospital. A DEXA scan should be scheduled to measure and evalu-
ate BMD. The results of the DEXA scan can be used to gauge the 
severity of bone loss, predict future fracture risk, make treatment 
decisions, and monitor changes in BMD related to age, medical con-
ditions, or therapeutic intervention. The provider should discuss 
initiation of antiresorptive therapy, outpatient physical therapy for 
gait training, smoking cessation, and alcohol intake moderation. 
By evaluating the initial routine laboratory test results, the pri-
mary care providers should make the decision on continu-
ing therapeutic cholecalciferol (vitamin D3) treatment and, if 
necessary, order further testing, such as serum protein elec-
trophoresis, 24-hour urine calcium, and 24-hour urine cre-
atinine, to delineate the etiology of the metabolic bone disease.
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DISCUSSION
The goal of this bone health improvement protocol was to ensure 
that patients with osteoporosis and fragility fractures receive qual-
ity care for their bone health in both the inpatient and outpatient 
settings. About 10 million Americans over the age of 50 have os-
teoporosis and that number will increase to 14 million by 2020.15 
These patients are high risk and should be monitored closely for 
osteoporosis in the setting of any fracture.  There is a large gap be-
tween what has been learned and what is applied by patients and 
health care providers.  The biggest problem is a lack of awareness of 
bone disease among both the public and health care professionals.32
Patients who have had a fragility fracture have hypovitaminosis 
D 73% of the time.48 This is in line with current levels in the United 
States and Canada in a population without fracture. A prospective 
randomized trial in 2009 demonstrated a trend toward a decrease 
in fracture incidence in patients who took daily vitamin D and cal-
cium supplementation.49 High dose vitamin D3 (≥ 300,000 IU) 
is efficacious in treating low levels of vitamin D and restoring the 
level to a normal limit.39 Kearns et al.50, however, concluded that a 
high dose of vitamin D3 (≥ 600,000 IU) at one time will have ad-
verse effects which could cause hypercalcemia or hypercalcinuria. 
Osteoporosis is thought to be caused by factors including age-re-
lated impairment of bone formation, decreased calcium and vitamin 
D intake, decreased physical activity, and estrogen’s positive effects 
on calcium balance in the intestines, kidneys, and bone.51 Provid-
ing patients with the adequate information to take control of their 
osteoporosis is crucial to the success of this protocol. Patient edu-
cation, such as the benefit of smoking cessation, should be empha-
sized, especially in the setting of fracture. Tobacco has been shown 
to hinder fracture healing and alcohol consumption of three or more 
units per day will have consequential effects on bone health, lead-
ing to lower BMD when compared with more moderate drinking.6 
Education on avoidance of preventable falls also has a major impact 
on reducing further fragility fractures as patients with osteoporo-
sis often experience muscle weakness, postural deformity, and poor 
balance.52 Patients who undergo tailored exercises and intervention 
have a decrease in fall rate in the community.53 These measures 
should assist in decreasing the rate of recurrent fragility fracture.
Elderly patients presenting with fragility fractures should 
be offered assessment with this protocol by orthopedic and/
or trauma surgeon teams, as they have a unique opportunity to 
diagnose, arrange follow-up, and ensure the patient is started 
on the appropriate therapy. The orthopedic and trauma sur-
geons should communicate clearly with the primary care phy-
sicians the need to explore and address the relevant causes.
Genetics and nutrition contribute to the rapid phase of bone 
loss in postmenopausal women and the slow phase of bone loss 
in aging women and men.32 These factors appear to be largely 
the result of estrogen deficiency. Estrogen is a hormone that is 
important throughout life to support bone development and main-
tenance in both men and women. Drugs, such as antiresorptives, that 
prevent bone breakdown have been effective in reducing the risk of 
future fractures. These drugs not only slow any further deteriora-
tion of the skeleton, but also allow for some repair and restoration 
of bone mass and strength. However, they cannot completely restore 
mechanical integrity because of the absence of an anabolic effect.
There are several possible barriers to implementation of this 
protocol in the current healthcare setting. The most notable is 
provider education. Healthcare providers of fragility fracture pa-
tients will need to be well educated on the protocol for it to be ef-
fective. These healthcare providers include orthopedic physicians, 
emergency room physicians, emergency room physician extenders, 
orthopedic mid-level providers, primary care providers, resident 
physicians, and nurses. After adequate education, the protocol 
implementation could be subjected to improvements that would 
incorporate potential patients into all aspects of the protocol. An-
other potential barrier was identified through a survey of physi-
cians which was cost of the workup necessary for osteoporosis.54 
Communication between orthopedic surgeons and primary care 
physicians also has been identified as a barrier that needs to be 
addressed.55 Increasing awareness of the responsibility and the 
opportunity providers have to make a substantial impact on this 
clinical problem would prevent secondary fragility fractures and 
decrease the morbidity and mortality of patients with underly-
ing metabolic bone disease. Other potential barriers include cost 
of therapy, patient reluctance, time and cost of diagnosing osteo-
porosis, special patient populations (e.g., uninsured or under-
insured, minorities) gender differences, lack of access to BMD 
testing, and a lack of time to address secondary prevention.56-57 
Comprehensive secondary prevention should consist of osteopo-
rosis assessment and treatment together with a fall risk assessment. 
With this protocol, secondary fragility fractures could be prevented.
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